Celldex Therapeutics, Inc (CLDX) — Analysis Summary
Celldex Therapeutics, Inc (CLDX) has a market cap of $2.47B with year-over-year revenue growth of -78.0%. Net margin stands at -16748.0%. The stock trades at a P/E ratio of -8.7.
Key Takeaways
- Revenue changed -78.0% year-over-year
- Net margin of -16748.0%
- P/E ratio of -8.7
Compared to other companies in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector, CLDX posted revenue growth of -78.0% and trades at a P/E of -8.7.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.